Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, AstraZeneca, NKI Partner to ID Colorectal Cancer Subtypes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia, AstraZeneca, and the Netherlands Cancer Institute today announced a collaboration to identify specific molecular subtypes of colorectal cancer in order to develop targeted therapies.

As part of the deal, Agendia will provide molecular data, bioinformatics support, and diagnostics expertise to AstraZeneca to define subpopulations within colorectal cancer, which kills about 500,000 people in the US and Europe each year, the partners said.

Further terms of the deal were not disclosed.

Bernard Sixt, CEO and co-founder of Agendia, said in a statement that the collaboration will benefit both direct participants as well as the scientific community by "providing a much greater understanding of the various disease types in the colorectal field." He added that a key feature of the partnership is that it may enable the development of companion diagnostics far more quickly than has been currently possible.

Rene Bernards, professor of molecular carcinogenesis at NKI and co-founder of Agendia, said that he and his colleagues have identified distinct molecular subtypes in colorectal cancer, each responding differently to different therapies. "Along with our new partners, we aim to identify drivers of the oncogenic process in each of these subtypes."

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.